EGFR and non-small cell lung carcinoma: Although the PD‐L1 TPS in tumors, smoking status, and location of metastatic lesions were known to be predictive factors for therapeutic effects of ICI treatment in NSCLC with wild‐type EGFR, there were no significant differences in this study.